Once-monthly treatment for diabetes shows promise
The drug (codename: HM11260C), developed by Hanmi Pharmaceutical, a novel GLP-1 agonist for the treatment of type 2 diabetes.
Hanmi has initiated a Phase ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
